LifePoint, Inc.
LFPI · OTC
Company research
LifePoint, Inc. (OTC: LFPI) is a healthcare company headquartered in Ontario, California, that focuses on the development, manufacturing, and sale of the IMPACT Test System, a specialized diagnostic testing and screening device. Founded in 1992 and formerly known as US Drug Testing, Inc. before rebranding in February 1998, the company serves a diverse range of markets including workplaces, emergency medical services, retail pharmacies, law enforcement, and home healthcare sectors. Led by CEO Richard Wadley and with approximately 52 full-time employees, LifePoint, Inc. operates as a small-cap company in the Medical Instruments & Supplies industry within the broader Healthcare sector. The company trades on the OTC markets with a current market capitalization of approximately $31,294 USD.
Research reports
This company report provides an updated fundamental snapshot of LFPI with automated analysis showing negligible market cap, deeply negative earnings, and zero scores across valuation, growth, performance, and financial health “Snowflake” factors, while highlighting illiquidity and outdated financial statements as key risks for investors.
StockExpertAI · March 16, 2026Lfpi Analyst ConsensusStockExpertAI’s narrative report lays out an explicit investment thesis around the IMPACT Test System and point‑of‑care diagnostics, discusses extreme reported margins, diversified end‑markets, and multiple growth opportunities, but pairs these with severe distress signals (Altman Z‑score in the danger zone, weak Piotroski F‑score), OTC liquidity and regulatory risks, and presents balanced bull and bear cases culminating in a Hold‑grade council score.
ValueInvesting.io · November 2, 2025LFPI Intrinsic ValueThis intrinsic value report applies several discounted cash flow and multiples-based models to LFPI and concludes an intrinsic value of 1.47 USD versus a near‑zero market price, framing the shares as massively undervalued with enormous implied upside, while detailing the valuation range, underlying assumptions on market risk premium, cost of equity and WACC, and acknowledging the highly extreme outputs that stem from the company’s tiny market cap and volatile inputs.